Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ PEX3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA542814
Description
Peptide sequence: KYGQKKIREI QEREAAEYIA QARRQYHFES NQRTCNMTVL SMLPTLREAL Sequence homology: Cow: 100%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rabbit: 100%; Rat: 100%; Zebrafish: 93%.
Peroxin 3, also known as PEX3 (peroxisomal biogenesis factor 3) or TRG18, is a 373 amino acid multi-pass membrane protein that localizes to peroxisomes and belongs to the Peroxin family. Expressed ubiquitously, Peroxin 3 interacts with Peroxin 19 and is involved in peroxisome biosynthesis and membrane vesicle assembly, as well as in the maintenance of peroxisomal integrity. Additionally, Peroxin 3 acts as a docking factor for Peroxin 19 and is required for the import of peroxisomal proteins. Defects in the gene encoding Peroxin 3 are the cause of peroxisome biogenesis disorder complementation group 12 (PBD-CG12) and Zellweger syndrome (ZwS), both of which arise from a failure of peroxisomal protein import.
Specifications
PEX3 | |
Polyclonal | |
Unconjugated | |
PEX3 | |
1700014F15Rik; 2810027F19Rik; 2900010N04Rik; PBD10A; Peroxin3; peroxin-3; peroxisomal assembly protein 3; peroxisomal assembly protein PEX3; Peroxisomal biogenesis factor 3; pex3; transformation-related protein 18; TRG18; zgc:56313 | |
Rabbit | |
Protein A | |
RUO | |
8504 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Immunohistochemistry, Western Blot | |
1 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
P56589 | |
PEX3 | |
Synthetic peptide directed towards the N-terminal of human PEX3 (aa 31-80). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction